News

StayinFront is a global provider of CRM systems and mobile sales force effectiveness tools. Using StayinFront CRM systems, which run on AdvantageMS National Provider Database, users can have

ALN-VSP is a systemically delivered RNAi therapeutic which includes two siRNAs intended to target two genes critical for the growth and development of cancer cells: vascular endothelial growth

Kodiac program includes two placebo controlled randomized Phase III studies and a randomized, open-label, placebo-controlled long term safety study. The two studies are designed to investigate the safety,

The solution, which will be launched as a generic in 100 milligrams per 5ml (20 milligrams per 1 ml), is intended to relieve moderate to severe acute and

During the lease period the parties may have further discussions to extend the alliance beyond the fifth anniversary. The tie up allows SkyePharma to hold its current contractual

The new facility is a contract manufacturing resource that uses aseptic barrier technology. Pharmalucence expects to take delivery of the isolated filling line by late Spring 2012. It

Earlier in November 2010, the company has signed an agreement with Roger Bullock, for the development of more effective clinical trials for this field. Currently, Synexus is in

The acquisition is expected to be done for around $175m which will include all outstanding shares and outstanding options. Allied CEO Sandy Young said after an examination of

Alpharadin, a highly targeted alpha-pharmaceutical, currently under clinical evaluation, is intended to improve survival in patients suffering from bone metastases from advanced cancer. Algeta has chosen Onet for